Compositions and methods for the treatment of sepsis
OwnerJohn Mansellinventor
Life of this patent
Estimating the term…
Abstract
Compositions disclosed herein comprise materials which (i) reduce the amount of one or more nitric oxide synthases present; (ii) reduce the level of expression of one or more nitric oxide synthases; and/or (iii) reduce the catalytic activity of one or more nitric oxide synthases is referred to herein as a nitric oxide nNOS disruptor (NOD).
Claims21
1-47. (canceled)
A composition comprising two materials selected from a material group, the material group consisting of (a) a neuronal nitric oxide synthase silencing nucleotide;
- (b) a neuronal nitric oxide synthase binding antibody;
- (c) an endothelial nitric oxide synthase silencing nucleotide;
- (d) an endothelial nitric oxide synthase binding antibody;
- (e) an inducible nitric oxide synthase silencing nucleotide;
- (f) an inducible nitric oxide synthase binding antibody;
- (g) a calcitonin gene-related peptide silencing nucleotide;
- (h) a calcitonin gene-related peptide binding antibody;
- (i) a disintegrin and metalloprotease peptide silencing nucleotide;
- (j) a disintegrin and metalloprotease binding antibody;
- (k) a bradykinin peptide silencing nucleotide;
- (l) a bradykinin binding antibody;
- (m) a substance P peptide silencing nucleotide;
- (n) a substance P binding antibody;
- (o) a histidine decarboxylase silencing nucleotide;
- (p) a histidine decarboxylase binding antibody;
- (q) an antihistamine;
- (r) a bradykinin antagonist;
- (s) a cyclooxygenase silencing nucleotide;
- (t) a cyclooxygenase binding antibody;
- (u) a small molecule prostacyclin inhibitor;
- (v) a prostacyclin synthase silencing nucleotide;
- and (w) a prostacyclin synthase binding antibody.
A medicament comprising a composition, wherein the composition comprises two materials selected from a material group, the material group consisting of (a) a neuronal nitric oxide synthase silencing nucleotide;
- (b) a neuronal nitric oxide synthase binding antibody;
- (c) an endothelial nitric oxide synthase silencing nucleotide;
- (d) an endothelial nitric oxide synthase binding antibody;
- (e) an inducible nitric oxide synthase silencing nucleotide;
- (f) an inducible nitric oxide synthase binding antibody;
- (g) a calcitonin gene-related peptide silencing nucleotide;
- (h) a calcitonin gene-related peptide binding antibody;
- (i) a disintegrin and metalloprotease peptide silencing nucleotide;
- (j) a disintegrin and metalloprotease binding antibody;
- (k) a bradykinin peptide silencing nucleotide;
- (l) a bradykinin binding antibody;
- (m) a substance P peptide silencing nucleotide;
- (n) a substance P binding antibody;
- (o) a histidine decarboxylase silencing nucleotide;
- (p) a histidine decarboxylase binding antibody;
- (q) an antihistamine;
- (r) a bradykinin antagonist;
- (s) a cyclooxygenase silencing nucleotide;
- (t) a cyclooxygenase binding antibody;
- (u) a small molecule prostacyclin inhibitor;
- (v) a prostacyclin synthase silencing nucleotide;
- and (w) a prostacyclin synthase binding antibody.
A method comprising the administration of a medicament to a subject having a clinical presentation of sepsis, wherein the medicament comprises a composition, wherein the composition comprises two materials selected from a material group, the material group consisting of (a) a neuronal nitric oxide synthase silencing nucleotide;
- (b) a neuronal nitric oxide synthase binding antibody;
- (c) an endothelial nitric oxide synthase silencing nucleotide;
- (d) an endothelial nitric oxide synthase binding antibody;
- (e) an inducible nitric oxide synthase silencing nucleotide;
- (f) an inducible nitric oxide synthase binding antibody;
- (g) a calcitonin gene-related peptide silencing nucleotide;
- (h) a calcitonin gene-related peptide binding antibody;
- (i) a disintegrin and metalloprotease peptide silencing nucleotide;
- (j) a disintegrin and metalloprotease binding antibody;
- (k) a bradykinin peptide silencing nucleotide;
- (l) a bradykinin binding antibody;
- (m) a substance P peptide silencing nucleotide;
- (n) a substance P binding antibody;
- (o) a histidine decarboxylase silencing nucleotide;
- (p) a histidine decarboxylase binding antibody;
- (q) an antihistamine;
- (r) a bradykinin antagonist;
- (s) a cyclooxygenase silencing nucleotide;
- (t) a cyclooxygenase binding antibody;
- (u) a small molecule prostacyclin inhibitor;
- (v) a prostacyclin synthase silencing nucleotide;
- and (w) a prostacyclin synthase binding antibody.
Dependencies are inferred from the claim text.